NINDS Network for Excellence in Neuroscience: Clinical Research Site at UC Davis

NINDS 神经科学卓越网络：加州大学戴维斯分校的临床研究中心

• 批准号: 10745254
• 负责人: Craig M. McDonald
• 金额: $ 44万
• 依托单位: UNIVERSITY OF CALIFORNIA AT DAVIS
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-07-06 至 2028-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10745254
• 关键词: Address; Adult; Affect; Biological Markers; California; Capital; Cell Therapy; Characteristics; Childhood; Cities; Clinic; Clinical; Clinical Investigator; Clinical Research; Clinical Trials; Clinical Trials Cooperative Group; Clinical Trials Network; Communities; Community Outreach; Country; Data; Development; Disease; Disease Management; Electronics; Environment; Faculty; Foundations; Functional disorder; Funding; Future; Gene therapy trial; Goals; Health system; Industry; Infrastructure; Institution; Link; Medicine; Mission; National Institute of Neurological Disorders and Stroke; Natural History; Neurology; Neurosciences; Neurosciences Research; Outcome; Patient Recruitments; Patients; Personal Satisfaction; Persons; Phase II Clinical Trials; Population; Population Scientist Supplement (R25); Positioning Attribute; Preparation; Protocols documentation; Public Health; Public Health Informatics; Quality of life; Regenerative Medicine; Research; Research Infrastructure; Research Personnel; Research Training; Resource Informatics; Resources; Scientist; Site; Standardization; System; Testing; Therapy Clinical Trials; Time; Training; Translational Research; United States National Institutes of Health; Universities; Vision; Work; biomarker validation; burden of illness; career; clinical outcome measures; clinical research site; design; digital health; drug development; drug discovery; experience; functional improvement; gene therapy; gene therapy clinical trial; improved; innovation; nervous system disorder; new therapeutic target; novel therapeutics; outreach; patient retention; programs; recruit; response; skills; sound; success; supportive environment; telehealth; translational research program

This proposal contributes to the NINDS Network for Excellence in Neuroscience (NeuroNEXT) by renewing a clinical research site at the University of California Davis Health System located in Sacramento, CA, the capital of the most populous state in the country and one of the most diverse and integrated cities in the U.S. The UC Davis NeuroNEXT clinical research site will continue to contribute to the mission of NINDS by reducing the burden of neurologic diseases, and contribute an infrastructure which expands the NINDS capability to test promising new therapies, increase the efficiency of clinical trials, and respond quickly as new opportunities arise to test promising treatments for people with neurological disorders. Our experience as an existing NeuroNEXT site, neuroscience research excellence at UC Davis - the most comprehensive campus in the University of California system, a robust translational research infrastructure housed in a nationally recognized, experienced, and competitively renewed NIH CTSA (the UC Davis CTSC), neuroscience research and research training excellence, an innovative collaborative drug development pipeline from University of California Drug Discovery Consortium, a national center of excellence in telehealth strategically positioned to promote community outreach, innovative digital health informatics for case identification and electronic outreach, a well-established R25 offering strong innovative training in Neurotherapeutics Discovery and Development for Academic Scientists, new institutional commitment to protect up to 70% time for research training for NeuroNEXT Fellows and a R25 pipeline of diverse trainees, a competitively renewed and robust Alpha Clinic gene and cell therapy clinical trial infrastructure which will contribute to a new Gene Therapy Consortium and gene therapy trials, and access to diverse patients with neurological disorders managed in a highly ranked regional health system with active clinical affiliations, all work synergistically to position UC Davis to continue to be an outstanding and innovative Clinical Research Site for the NeuroNEXT network. UC Davis NeuroNEXT aims to: 1) Leverage existing resources and expertise to serve as a NeuroNEXT hub for efficiently implementing scientifically sound, possibly biomarker-informed exploratory multicenter neuroscience clinical trials evaluating promising therapies, and increase the efficiency and quality of trials conducted at UC Davis NeuroNEXT; 2) Provide local and regional community outreach to improve patient recruitment and retention and fully integrate community partners into the translational research enterprise; 3) Efficiently utilize, diversify, and leverage innovative digital health informatics resources for trials; 4) Provide collaborative and innovative clinical research training and a supportive environment for diverse early-career investigators to develop additional research skills and become independent clinical investigators; and 5) Partner with the NeuroNEXT Gene Therapy Consortium and UC Davis Alpha Clinic to efficiently conduct gene therapy trials. Our accomplishments to date – locally, regionally, and nationally – provide an outstanding foundation for future success.

该提案通过在加利福尼亚州萨克拉曼多的加利福尼亚大学戴维斯大学卫生系统上更新一个临床研究网站，为加利福尼亚州萨克拉曼多市的临床研究站点续签，这项提案为NINDS神经科学卓越网络（Neuronext）做出了贡献，该系统是该国人口最多的州的首都，并且是美国最多样化和最多样化和整合的城市之一，它将继续由UC Davis davis davis clian clian clinical Researt撰写。疾病，并贡献了基础设施，该疾病扩大了NINDS测试有希望的新疗法，提高临床试验效率的能力，并随着新的机会来测试神经系统疾病患者的有希望治疗的新机会，并迅速做出反应。 Our experience as an existing NeuroNEXT site, neuroscience research excellence at UC Davis - the most comprehensive campus in the University of California system, a robust translational research Infrastructure housed in a nationally recognized, experienced, and competitively renewed NIH CTSA (the UC Davis CTSC), neuroscience research and research training excellent, an innovative collaborative drug development pipeline from University of California Drug Discovery Consortium, a national center of Excellence in telehealth strategically positioned to promote community outreach, innovative digital health informatives for case identification and electronic outreach, a well-established R25 offering strong innovative training in Neurotherapeutics Discovery and Development for Academic Sc​​ientists, new institutional commitment to protect up to 70% time for research training for NeuroNEXT Fellows and a R25 pipeline of divers trainees, a competitively renewed and robust Alpha临床基因和细胞疗法临床试验基础设施将有助于新的基因治疗联盟和基因治疗试验，并在高度排名的区域卫生系统中管理具有神经系统疾病的潜水患者，并具有活跃的临床分支机构，所有工作都可以协同工作，使UC Davis继续以UC Davis的良好和Innovitial Clinial Clangial Change网站定位。 UC Davis Neuronext的目的是：1）利用现有资源和专业知识来充当神经网络枢纽，以科学的方式进行有效的实施，可能具有生物标志物的探索性探索性探索性多中心神经科学临床试验，评估疗法，并提高在UC Davis Neuronext上进行试验的效率和质量； 2）提供地方和区域社区的宣传，以改善患者招聘和保留率，并将社区伙伴完全整合到翻译的研究企业中； 3）有效利用，多样化和利用创新的数字健康信息资源进行试验； 4）提供协作和创新的临床研究培训，并为潜水员早期研究人员提供额外研究技能并成为独立临床研究人员的支持环境； 5）与Neuronext基因治疗联盟和UC Davis Alpha诊所合作，有效地进行基因治疗试验。迄今为止，我们在本地，地区和全国范围内取得的成就为未来成功提供了杰出的基础。